AU2017295004B2 - Process for the production of a DNA vaccine for cancer immunotherapy - Google Patents

Process for the production of a DNA vaccine for cancer immunotherapy Download PDF

Info

Publication number
AU2017295004B2
AU2017295004B2 AU2017295004A AU2017295004A AU2017295004B2 AU 2017295004 B2 AU2017295004 B2 AU 2017295004B2 AU 2017295004 A AU2017295004 A AU 2017295004A AU 2017295004 A AU2017295004 A AU 2017295004A AU 2017295004 B2 AU2017295004 B2 AU 2017295004B2
Authority
AU
Australia
Prior art keywords
antigen
leu
ser
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017295004A
Other languages
English (en)
Other versions
AU2017295004A1 (en
Inventor
Heinz Lubenau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEC OncoImmunity AS
Original Assignee
NEC OncoImmunity AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEC OncoImmunity AS filed Critical NEC OncoImmunity AS
Publication of AU2017295004A1 publication Critical patent/AU2017295004A1/en
Application granted granted Critical
Publication of AU2017295004B2 publication Critical patent/AU2017295004B2/en
Assigned to NEC Oncolmmunity AS reassignment NEC Oncolmmunity AS Request for Assignment Assignors: VAXIMM AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017295004A 2016-07-13 2017-07-12 Process for the production of a DNA vaccine for cancer immunotherapy Active AU2017295004B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001550 2016-07-13
EP16001550.9 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Publications (2)

Publication Number Publication Date
AU2017295004A1 AU2017295004A1 (en) 2019-01-03
AU2017295004B2 true AU2017295004B2 (en) 2020-08-13

Family

ID=56418345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017295004A Active AU2017295004B2 (en) 2016-07-13 2017-07-12 Process for the production of a DNA vaccine for cancer immunotherapy

Country Status (13)

Country Link
US (2) US10821163B2 (enExample)
EP (1) EP3484503A1 (enExample)
JP (2) JP7098599B2 (enExample)
KR (3) KR20230079514A (enExample)
CN (1) CN109475614A (enExample)
AU (1) AU2017295004B2 (enExample)
BR (1) BR112019000657A2 (enExample)
CA (1) CA3028549A1 (enExample)
IL (1) IL263568A (enExample)
MX (1) MX2019000415A (enExample)
RU (1) RU2019100079A (enExample)
SG (1) SG11201811258UA (enExample)
WO (1) WO2018011289A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190117603A (ko) 2017-02-17 2019-10-16 백심 아게 신규 vegfr-2 표적화 면역요법상 접근법
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
AU2021208400A1 (en) 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
US20250340919A1 (en) * 2022-06-30 2025-11-06 Shimadzu Corporation Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014173542A1 (en) * 2013-04-25 2014-10-30 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
WO2015090584A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2714071T (lt) * 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
BR112014015706A2 (pt) 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
SG11201500054QA (en) * 2012-07-05 2015-03-30 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014173542A1 (en) * 2013-04-25 2014-10-30 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
WO2015090584A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
BR112019000657A2 (pt) 2019-04-24
KR20190027834A (ko) 2019-03-15
IL263568A (en) 2019-01-31
WO2018011289A1 (en) 2018-01-18
JP2019521154A (ja) 2019-07-25
JP2022097591A (ja) 2022-06-30
RU2019100079A (ru) 2020-08-13
US10821163B2 (en) 2020-11-03
KR20230079514A (ko) 2023-06-07
CN109475614A (zh) 2019-03-15
US11590215B2 (en) 2023-02-28
JP7098599B2 (ja) 2022-07-11
AU2017295004A1 (en) 2019-01-03
EP3484503A1 (en) 2019-05-22
SG11201811258UA (en) 2019-01-30
US20220072112A1 (en) 2022-03-10
US20190183996A1 (en) 2019-06-20
CA3028549A1 (en) 2018-01-18
KR20260047288A (ko) 2026-04-07
MX2019000415A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
KR102090612B1 (ko) 췌장암 환자용 dna 백신
KR20230079514A (ko) 암 면역요법용 dna 백신을 제조하기 위한 방법
JP6416877B2 (ja) ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター
CN107995868B (zh) 用于联合治疗的vegfr-2靶向dna疫苗
KR20190125481A (ko) 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
AU2018222777B9 (en) Novel VEGFR-2 targeting immunotherapy approach
JP2024167172A (ja) 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
KR20190082227A (ko) 병용 요법용 wt1 표적화 dna 백신
KR20220161444A (ko) 새로운 살모넬라-기반의 코로나바이러스 백신
KR20220128638A (ko) 항생제와 조합되는 살모넬라-기반의 dna 백신
CN120944823A (zh) 特异性结合Claudin18.2的嵌合抗原受体免疫细胞及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEC ONCOLMMUNITY AS

Free format text: FORMER OWNER(S): VAXIMM AG